Synopsis
Synopsis
0
EU WC
0
Australia
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. Neomycin
2. Neomycin Palmitate
3. Neomycin Sulfate
1. Neomycin Sulfate
2. 1405-10-3
3. Neomycin Trisulfate Hydrate
4. Akos016010116
| Molecular Weight | 712.7 g/mol |
|---|---|
| Molecular Formula | C23H48N6O17S |
| Hydrogen Bond Donor Count | 15 |
| Hydrogen Bond Acceptor Count | 23 |
| Rotatable Bond Count | 9 |
| Exact Mass | 712.27966526 g/mol |
| Monoisotopic Mass | 712.27966526 g/mol |
| Topological Polar Surface Area | 436 Ų |
| Heavy Atom Count | 47 |
| Formal Charge | 0 |
| Complexity | 953 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 18 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Neomycin sulfate |
| Drug Label | Neomycin Sulfate Tablets, USP, for oral administration, contain neomycin which is an antibiotic obtained from the metabolic products of the actinomycete Streptomycesfradiae. Structurally, neomycin sulfate may be represented as follows:Chemically, i... |
| Active Ingredient | Neomycin sulfate |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 500mg |
| Market Status | Prescription |
| Company | Oman Pharm Products; Teva; X Gen Pharms |
| 2 of 2 | |
|---|---|
| Drug Name | Neomycin sulfate |
| Drug Label | Neomycin Sulfate Tablets, USP, for oral administration, contain neomycin which is an antibiotic obtained from the metabolic products of the actinomycete Streptomycesfradiae. Structurally, neomycin sulfate may be represented as follows:Chemically, i... |
| Active Ingredient | Neomycin sulfate |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 500mg |
| Market Status | Prescription |
| Company | Oman Pharm Products; Teva; X Gen Pharms |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
Protein Synthesis Inhibitors
Compounds which inhibit the synthesis of proteins. They are usually ANTI-BACTERIAL AGENTS or toxins. Mechanism of the action of inhibition includes the interruption of peptide-chain elongation, the blocking the A site of ribosomes, the misreading of the genetic code or the prevention of the attachment of oligosaccharide side chains to glycoproteins. (See all compounds classified as Protein Synthesis Inhibitors.)
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13615
Submission : 1998-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-02-26
Pay. Date : 2013-02-13
DMF Number : 13378
Submission : 1998-09-01
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 271
Submission : 1940-01-01
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 270
Submission : 1940-01-01
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 262
Submission : 1940-01-01
Status : Inactive
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 124
Submission : 1953-07-23
Status : Inactive
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Neomycin Sulfate, Micronised And Non-micronised
Certificate Number : R1-CEP 1999-184 - Rev 03
Status : Valid
Issue Date : 2020-04-21
Type : Chemical
Substance Number : 197
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R1-CEP 2017-006 - Rev 00
Status : Valid
Issue Date : 2023-04-13
Type : Chemical and TSE
Substance Number : 197

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R1-CEP 2001-317 - Rev 00
Status : Valid
Issue Date : 2010-09-07
Type : Chemical
Substance Number : 197

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R1-CEP 2011-029 - Rev 01
Status : Valid
Issue Date : 2020-02-27
Type : Chemical and TSE
Substance Number : 197

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2022-013 - Rev 01
Status : Valid
Issue Date : 2023-02-15
Type : Chemical and TSE
Substance Number : 197

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] NDC Package Code : 69988-0031
Start Marketing Date : 2012-03-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/1)
Marketing Category : DRUG FOR FURTHER PROCESSING

NDC Package Code : 51551-0307
Start Marketing Date : 2005-07-07
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 38779-0348
Start Marketing Date : 2021-01-19
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT

NDC Package Code : 51927-1167
Start Marketing Date : 2002-07-19
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...

NDC Package Code : 0009-5238
Start Marketing Date : 2014-07-03
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 0009-5238
Start Marketing Date : 2014-07-03
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 66405-0005
Start Marketing Date : 2017-12-29
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 51671-0010
Start Marketing Date : 2010-12-17
End Marketing Date : 2027-06-08
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 55718-147
Start Marketing Date : 2017-04-07
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : DRUG FOR FURTHER PROCESSING

NDC Package Code : 65876-0004
Start Marketing Date : 2017-01-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1[BAU]/[BAU])
Marketing Category : BULK INGREDIENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : FML Neo Liquifilm Ophthalmic Suspension
Dosage Form : OPD
Dosage Strength : 5mg/ml
Packaging : 5X1mg/ml
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE
Brand Name : POLY-PRED
Dosage Form : SUSPENSION/DROPS;OPHTHALMIC
Dosage Strength : EQ 0.35% BASE;10,000 UNITS/ML;0.5%
Packaging :
Approval Date : 1982-01-01
Application Number : 50081
Regulatory Info : DISCN
Registration Country : USA
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
HYDROCORTISONE; NEOMYCIN SULFATE
Brand Name : NEO-CORT-DOME
Dosage Form : CREAM;TOPICAL
Dosage Strength : 1%;EQ 3.5MG BASE/GM
Packaging :
Approval Date : 1984-06-05
Application Number : 50237
Regulatory Info : DISCN
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
HYDROCORTISONE; NEOMYCIN SULFATE
Brand Name : NEO-CORT-DOME
Dosage Form : CREAM;TOPICAL
Dosage Strength : 0.5%;EQ 3.5MG BASE/GM
Packaging :
Approval Date : 1984-06-05
Application Number : 50237
Regulatory Info : DISCN
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE
Brand Name : NEO-CORT-DOME
Dosage Form : SUSPENSION/DROPS;OTIC
Dosage Strength : 2%;1%;EQ 0.35% BASE
Packaging :
Approval Date : 1982-01-01
Application Number : 50238
Regulatory Info : DISCN
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
NEOMYCIN SULFATE; POLYMYXIN B SULFATE
Brand Name : NEOSPORIN
Dosage Form : CREAM;TOPICAL
Dosage Strength : EQ 3.5MG BASE/GM;10,000 UNITS/GM
Packaging :
Approval Date : 1985-01-14
Application Number : 50176
Regulatory Info : DISCN
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : RX
Registration Country : USA
DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
Brand Name : MAXITROL
Dosage Form : SUSPENSION/DROPS;OPHTHALMIC
Dosage Strength : 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML
Packaging :
Approval Date : 1982-01-01
Application Number : 50023
Regulatory Info : RX
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
Brand Name : CORTISPORIN
Dosage Form : OINTMENT;TOPICAL
Dosage Strength : 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Packaging :
Approval Date : 1984-05-04
Application Number : 50168
Regulatory Info : DISCN
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
Brand Name : CORTISPORIN
Dosage Form : SUSPENSION/DROPS;OPHTHALMIC
Dosage Strength : 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML
Packaging :
Approval Date : 1982-01-01
Application Number : 50169
Regulatory Info : DISCN
Registration Country : USA

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : DISCN
Registration Country : USA
HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
Brand Name : CORTISPORIN
Dosage Form : CREAM;TOPICAL
Dosage Strength : 0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Packaging :
Approval Date : 1985-08-09
Application Number : 50218
Regulatory Info : DISCN
Registration Country : USA

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Dosage Form : Tablet
Grade : Oral
Dosage Form : Cream / Lotion / Ointment
Grade : Topical, Parenteral
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Application : Fillers, Diluents & Binders
Excipient Details : Microlose (Lactose Monohydrate & Microcrystalline Cellulose) is used as a diluent in oral dosage forms such as tablets.
Pharmacopoeia Ref : USP-NF,BP,EP,IP
Technical Specs : Lactose Monohydrate – 40%, Microcrystalline cellulose – 60%
Ingredient(s) : Lactose Monohydrate
Dosage Form : Softgels
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Application : Fillers, Diluents & Binders
Excipient Details : Starlose P40 (Starch & Lactose Monohydrate) is used as a diluent in oral dosage forms such as tablets.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dosage Form : Gel
Grade : Parenteral, Oral, Topical
Dosage Form : Tablet
Grade : Oral, Topical
Dosage Form : Injectable / Parenteral
Grade : Parenteral
Application : Parenteral
Excipient Details : Cholesterol is used as a sustained release material for drug delivery systems in injectable formulations.
Dosage Form : Injectable / Parenteral
Grade : Parenteral
Brand Name : Lactose Monohydrate
Application : Parenteral
Excipient Details : Lactose monohydrate is used as a diluent in inhalation and lyophilized preparations.
Dosage Form : Injectable / Parenteral
Grade : Parenteral, Oral, Topical
Application : Solubilizers
Excipient Details : Poloxamer 188 is used as a solubilizer, emulsifier, stabilizer in parenteral, OSDs & topical formulations such as creams, gels & lotions.
Pharmacopoeia Ref : ChP/USP/EP
Technical Specs : Oxyethylene unit: 75%-85%, Oxypropylene unit: 25%-30%
Ingredient(s) : Poloxamer 188
Dosage Form : Cream / Lotion / Ointment
Grade : Topical
Brand Name : Polyoxyl 20 Docosyl Ether
Application : Topical
Excipient Details : Polyoxyl 20 docosyl ether is used as a solubilizing agent and emulsifier in topical formulations.
Dosage Form : Cream / Lotion / Ointment
Grade : Parenteral, Oral, Topical
Dosage Form : Cream / Lotion / Ointment
Grade : Topical, Oral
Dosage Form : Injectable / Parenteral
Grade : Parenteral, Oral, Topical
Dosage Form : Injectable / Parenteral
Grade : Parenteral, Oral, Topical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dosage Form : Tablet
Grade : Oral
Application : Solubilizers
Excipient Details : PVP K30 is used as a binder, solubilizer, film-forming agent, and stabilizer in pharmaceutical formulations.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dosage Form : Capsule
Grade : Not Available
Application : Fillers, Diluents & Binders
Excipient Details : Tablet film coating, binders , main material of plant capsules.
Pharmacopoeia Ref : USP/BP/EP/CP
Technical Specs : Not Available
Ingredient(s) : Hydroxypropyl Methyl Cellulose
Dosage Form : Tablet
Grade : Not Available
Brand Name : Magnesium Stearate
Application : Lubricants & Glidants
Excipient Details : Lubricants, Anti-adhesive, Glidant
Dosage Form : Tablet
Grade : Not Available
Application : Emulsifying Agents
Excipient Details : Glidant; Emulsion Stabilizer; Anti-caking Agent.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dosage Form : Tablet
Grade : Oral
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dosage Form : Capsule
Grade : Oral
Application : Fillers, Diluents & Binders
Pharmacopoeia Ref : Conforms to USP-NF, Ph.Eur., J...
Technical Specs : Density- Tapped density- 857 g/l, Bulk density- 589 g/l; Particle size- D10- 5 ?m, D50- 40 ?m, D90-...
Ingredient(s) : Lactose Monohydrate
Excipients Web Link
Dosage Form : Tablet
Grade : Oral
Application : Fillers, Diluents & Binders
Pharmacopoeia Ref : Conforms to USP-NF, Ph.Eur., J...
Technical Specs : Density- Tapped density- 716 g/l, Bulk density- 599 g/l; Particle size- D10-50 ?m, D50- 120 ?m, D90-...
Ingredient(s) : Lactose Monohydrate
Dosage Form : Tablet
Grade : Oral
Application : Direct Compression
Pharmacopoeia Ref : Conforms to Ph. Eur., Lactose ...
Technical Specs : Density- Tapped density- 906 g/l, Bulk density- 722 g/l; Particle size- D10-15 ?m, D50- 170 ?m, D90-...
Ingredient(s) : Anhydrous Lactose
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
52
PharmaCompass offers a list of Neomycin Sulfate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Neomycin Sulfate manufacturer or Neomycin Sulfate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Neomycin Sulfate manufacturer or Neomycin Sulfate supplier.
A BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1, including repackagers and relabelers. The FDA regulates BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 supplier is an individual or a company that provides BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 active pharmaceutical ingredient (API) or BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 finished formulations upon request. The BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 suppliers may include BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 API manufacturers, exporters, distributors and traders.
click here to find a list of BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 DMF (Drug Master File) is a document detailing the whole manufacturing process of BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 active pharmaceutical ingredient (API) in detail. Different forms of BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 DMFs exist exist since differing nations have different regulations, such as BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 DMF submitted to regulatory agencies in the US is known as a USDMF. BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 USDMF includes data on BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 Drug Master File in Japan (BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 JDMF) empowers BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 JDMF during the approval evaluation for pharmaceutical products. At the time of BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 Drug Master File in Korea (BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1. The MFDS reviews the BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 KDMF as part of the drug registration process and uses the information provided in the BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 KDMF to evaluate the safety and efficacy of the drug.
After submitting a BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 suppliers with KDMF on PharmaCompass.
A BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 CEP of the European Pharmacopoeia monograph is often referred to as a BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 Certificate of Suitability (COS). The purpose of a BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 to their clients by showing that a BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 CEP has been issued for it. The manufacturer submits a BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 CEP (COS) as part of the market authorization procedure, and it takes on the role of a BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 CEP holder for the record. Additionally, the data presented in the BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 DMF.
A BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 suppliers with NDC on PharmaCompass.
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 GMP manufacturer or BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 GMP API supplier for your needs.
A BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 CoA (Certificate of Analysis) is a formal document that attests to BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1's compliance with BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 specifications and serves as a tool for batch-level quality control.
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 CoA mostly includes findings from lab analyses of a specific batch. For each BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 may be tested according to a variety of international standards, such as European Pharmacopoeia (BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 EP), BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE-1 USP).